Drug intelligence / Profile preview

TG-1702

Development stage: Unknown
Lead developer: TG Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**TG-1702** is an orally available, covalently bound and highly selective Bruton tyrosine kinase (BTK) inhibitor developed for the treatment of B-cell malignancies, primarily targeting chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). TG-1702 is designed to be more selective for BTK, with superior selectivity and reduced off-target kinase inhibition compared to earlier generations of BTK inhibitors. It may be used as monotherapy or in combination regimens (notably with umbralisib and ublituximab, the so-called "U2" regimen). TG-1702 has demonstrated promising objective response rates and an encouraging safety profile in early clinical trials.

Other names: SHR-1266SHR1266SHR 1266

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on TG-1702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG-1702.

Explore the full profile